SEC Form 4 · accession 0000905718-15-000774
Celldex Therapeutics, Inc. · CLDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Avery W Catlin
Officer — Sr. VP & CFO
Period of report
Sep 11, 2015
Accepted (ET)
Sep 14, 2015 · 8:21 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000744218
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.001 per shareF1 | Sep 11, 2015 | M | 10,000 | $4.50 | A | 35,109 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock OptionF2 | $4.50 | Sep 11, 2015 | M | 10,000 | D | Jan 21, 2013 | Jan 21, 2020 | Common Stock | 10,000 | 7,847 | D |
Explanation of responses
- F1Includes 500 shares of common stock acquired under the Company's 2004 Employee Stock Purchase Plan on June 30, 2015.
- F2As of January 21, 2014, the option was fully vested.